Clovis Expands Portfolio of Targeted Cancer Drugs with EOS Purchase

By Heather Cartwright

Pharma Deals Review: Vol 2013 Issue 12 (Table of Contents)

Published: 2 Dec-2013

DOI: 10.3833/pdr.v2013.i12.1994     ISSN: 1756-7874

Section: Mergers & Acquisitions



Putting its share price gains to good use, Clovis Oncology has acquired the Italian cancer drug developer Ethical Oncology Sciences (EOS) for an upfront consideration of US$200 M, including US$190 M in Clovis common stock and US$10 M in cash...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details